PISCATAWAY, N.J. – Camber Pharmaceuticals has launched topiramate extended-release capsules, USP, a generic equivalent of Trokendi XR from Supernus Pharmaceuticals, expanding its portfolio of treatments for epilepsy and migraine prevention.
The company announced Tuesday that the medication is available in 25 mg, 50 mg, 100 mg, and 200 mg strengths, with each strength packaged in 30-count bottles.
Topiramate extended-release capsules are indicated for the treatment of partial-onset and primary generalized tonic-clonic seizures in patients 6 years and older. The medication can also be used as adjunctive therapy for seizures associated with Lennox-Gastaut syndrome and for migraine prevention in patients 12 years and older.
According to figures cited by Camber, nearly 40 million Americans experience migraines, and approximately 3.4 million U.S. adults live with epilepsy. The company said the launch supports its efforts to expand access to affordable treatment options for patients with neurological conditions.
Additional product details and prescribing information are available on Camber’s website.
Submit Your Press Release
Have news to share? Send us your press releases and announcements.
Send Press Release